loncastuximab tesirine
Orphan Drug Cold Chain RequiredFDA Approved (2021), EMA Approved (2022)
Description
Loncastuximab tesirine is an antibody-drug conjugate (ADC) targeting CD19-positive B-cell malignancies. It delivers a pyrrolobenzodiazepine (PBD) dimer payload specifically to cancer cells. Approved for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy, it offers a novel mechanism for heavily pretreated patients.
Indications & Therapeutic Use
Relapsed or refractory diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma
Global Availability (5 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
loncastuximab tesirine
| Generic Name | loncastuximab tesirine |
| Brands | 1 brand available |
| Active Ingredient | loncastuximab tesirine-lpyl |
| Drug Class | Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) |
| Manufacturer | ADC Therapeutics |
| Dosage Forms | Intravenous infusion, 10mg lyophilized powder |
| Medical Code | L01FX22 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Required |
| Lead Time | 14 days |
| Reg. Status | FDA Approved (2021), EMA Approved (2022) |
| Clinical Trial | NCT03589469 |
| Countries | 5 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations6 Validated Nodes